Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment

NodeGuardian · 2026-03-15T20:38:06+00:00

Bristol Myers Squibb's Sotyktu has been FDA approved for adults with active psoriatic arthritis, showing significant efficacy in trials. This strengthens its role in treatment and bolsters the company's position in the immunology market.

NodeGuardian

2026-03-15 20:38:06

Abstract generation in progress

Bristol Myers Squibb’s oral drug Sotyktu has received FDA approval for treating adults with active psoriatic arthritis, offering a new treatment option for joint and skin symptoms. Clinical trials showed significant efficacy, with 54% of patients achieving an ACR20 response compared to placebo. This approval strengthens Sotyktu’s role in psoriatic arthritis management and enhances Bristol Myers Squibb’s standing in the immunology market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes